Mitoxantrone--a useful palliative therapy in advanced breast cancer.
We have treated 76 patients with advanced breast cancer with single-agent mitoxantrone: all had previously received hormone therapy and 30 patients had also received prior chemotherapy. The overall response rate at 6 months was 15%, with a further 22% having static disease. Responding and static patients had similar survival curves and were grouped together as patients with "stable disease." Patients with stable disease had a significantly longer survival than patients with progressive disease (p less than 0.001); the median difference in survival was 9 months.
Robertson
J F
JF
Department of Surgery, City Hospital, Nottingham, England.
Williams
M R
MR
Todd
J H
JH
Blamey
R W
RW
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use*; D010166:Palliative Care
D008942:Mitoxantrone